XNASAPM
Market cap3mUSD
Dec 24, Last price
0.84USD
1D
14.50%
1Q
-59.22%
IPO
-99.38%
Name
APTORUM GROUP LTD
Chart & Performance
Profile
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | |||||||
Revenues | 431 -66.71% | 1,296 -15.95% | 1,542 69.15% | ||||
Cost of revenue | 10,034 | 18,400 | 20,126 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (9,603) | (17,105) | (18,584) | ||||
NOPBT Margin | |||||||
Operating Taxes | (6,211) | (1,826) | |||||
Tax Rate | |||||||
NOPAT | (9,603) | (10,894) | (16,758) | ||||
Net income | (2,825) -46.85% | (5,314) -78.98% | (25,288) -457.84% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 1,576 | 5 | 4,000 | ||||
BB yield | -14.23% | -0.27% | -7.61% | ||||
Debt | |||||||
Debt current | 125 | 6,324 | 193 | ||||
Long-term debt | 3,383 | 872 | 241 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (14,596) | (4,534) | (12,090) | ||||
Cash flow | |||||||
Cash from operating activities | (7,724) | (12,319) | (14,652) | ||||
CAPEX | (3) | (187) | (138) | ||||
Cash from investing activities | 625 | 2,445 | 16,507 | ||||
Cash from financing activities | 4,092 | 6,625 | 2,781 | ||||
FCF | (8,138) | (10,035) | (15,546) | ||||
Balance | |||||||
Cash | 2,005 | 1,985 | 8,368 | ||||
Long term investments | 16,099 | 9,745 | 4,157 | ||||
Excess cash | 18,083 | 11,665 | 12,448 | ||||
Stockholders' equity | (77,635) | (37,475) | (26,001) | ||||
Invested Capital | 96,302 | 52,163 | 43,724 | ||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 4,521 | 357 | 3,503 | ||||
Price | 2.45 -55.49% | 5.50 -63.33% | 15.00 -39.27% | ||||
Market cap | 11,070 463.79% | 1,964 -96.26% | 52,551 -32.53% | ||||
EV | (12,989) | (10,449) | 34,359 | ||||
EBITDA | (8,478) | (15,897) | (17,391) | ||||
EV/EBITDA | 1.53 | 0.66 | |||||
Interest | 121 | 147 | 94 | ||||
Interest/NOPBT |